Red Avenue New Materials Group (603650) Fair Value & Analysis
Basic Materials · CN · Market cap 38.1B CNY
Analysis
Red Avenue New Materials Group (603650) currently trades at ¥69.16, while our model-based Fair Value estimate is ¥8.35 — implying the stock looks roughly 87.9% overvalued today. We read business quality at 94/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Red Avenue New Materials Group Co., Ltd. engages in the research, development, production, processing, and sales of fine chemical raw materials, chemical products, rubber and plastic processing aids, accelerators, microelectronic materials, and biodegradable plastic in China and internationally. The company offers resins, such as tackifying resin, P-tert-butyl Phenol formaldehyde tackifying resin, P-octyl Phenol formaldehyde tackifying resin, straight Phenol formaldehyde tackifying resin, tall oil modification Phenol formaldehyde resin, CNSL modified phenol formaldehyde reinforcing resin, and resorcinol formaldehyde resin, as well as curing, wet grp, anti-tear, tread, and sidewall resin. It also provides rubber processing aids, silica and functional additives, environment friendly chemical peptizer, anti-reversion agent, homogenizer, and coupling agent for CB; and vulcanizing agent, tackifier and silca activator, silica and silane, high styrene resin and antioxidant, rubber wax, tre…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.